Comparative Pharmacology
Head-to-head clinical analysis: LO OVRAL 28 versus SOJOURN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO OVRAL 28 versus SOJOURN.
LO/OVRAL-28 vs SOJOURN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
400 mg orally once daily
None Documented
None Documented
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive